25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). - Evidence Based Medicine on FHIR Implementation Guide v2.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Active as of 2024-12-19

Generated Narrative: Citation 179617

version: 9; Last updated: 2024-11-22 19:15:57+0000

Profile: JournalArticleCitation

url: Citation 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

identifier: FEvIR Object Identifier/https://fevir.net/FOI/179617, https://pubmed.ncbi.nlm.nih.gov/25301760, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.49

version: 2.0.0-ballot

title: 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

Citation Classification Type fevir-platform-use: FEvIR Platform Use

Medline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2016-04-07

lastReviewDate: 2022-12-08

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source
classifier: MEDLINE

classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2014-07-23

statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2014-09-19

statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2014-10-11 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2014-10-11 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2016-04-08 06:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/25301760, https://doi.org/10.1016/j.eururo.2014.09.032, pii/S0302-2838(14)00969-5
Titles
- Type Language Text
* Primary title English
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Abstracts
- Text Copyright
*
BACKGROUND: Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa--the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)--includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort. OBJECTIVE: Describe survival outcomes, along with current treatment standards and factors associated with prognosis, to inform future trial design in this patient group. DESIGN, SETTING, AND PARTICIPANTS: STAMPEDE trial control arm comprising men newly diagnosed with M1 disease who were recruited between October 2005 and January 2014. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and failure-free survival (FFS) were reported by primary disease characteristics using Kaplan-Meier methods. Hazard ratios and 95% confidence intervals (CIs) were derived from multivariate Cox models. RESULTS AND LIMITATIONS: A cohort of 917 men with newly diagnosed M1 disease was recruited to the control arm in the specified interval. Median follow-up was 20 mo. Median age at randomisation was 66 yr (interquartile range [IQR]: 61-71), and median prostate-specific antigen level was 112 ng/ml (IQR: 34-373). Most men (n=574; 62%) had bone-only metastases, whereas 237 (26%) had both bone and soft tissue metastases; soft tissue metastasis was found mainly in distant lymph nodes. There were 238 deaths, 202 (85%) from PCa. Median FFS was 11 mo; 2-yr FFS was 29% (95% CI, 25-33). Median OS was 42 mo; 2-yr OS was 72% (95% CI, 68-76). Survival time was influenced by performance status, age, Gleason score, and metastases distribution. Median survival after FFS event was 22 mo. Trial eligibility criteria meant men were younger and fitter than general PCa population. CONCLUSIONS: Survival remains disappointing in men presenting with M1 disease who are started on only long-term ADT, despite active treatments being available at first failure of ADT. Importantly, men with M1 disease now spend the majority of their remaining life in a state of castration-resistant relapse. PATIENT SUMMARY: Results from this control arm cohort found survival is relatively short and highly influenced by patient age, fitness, and where prostate cancer has spread in the body.

Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

relatesTo
type: comment-in
classifier: Comment
citation:
Eur Urol. 2015 Jun;67(6):1039-1041. doi: 10.1016/j.eururo.2014.12.004

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/25544634/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25544634
relatesTo
type: comment-in
classifier: Comment
citation:
J Urol. 2016 Feb;195(2):350. doi: 10.1016/j.juro.2015.10.165

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/26852973/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26852973
publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1873-7560, ISOAbbreviation/Eur Urol, ISSN Linking/0302-2838, Medline Title Abbreviation/Eur Urol, NLM Unique ID/7512719
title: European urology
publisherLocation: Switzerland
citedMedium: Internet
volume: 67
issue: 6
articleDate: 2015-06
publicationDateText: 2015-Jun
language: English
pageString: 1028-1038
publicationForm
citedMedium: Internet without issue
articleDate: 2014-10-06
webLocation
classifier: Abstract
url: https://pubmed.ncbi.nlm.nih.gov/25301760/
webLocation
classifier: DOI Based
url: https://doi.org/10.1016/j.eururo.2014.09.032
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Keyword
artifactAssessment: Keywords provided by NOTNLM
classification
type: Chemical
classifier: Androgen Antagonists, Taxoids, Docetaxel, Prostate-Specific Antigen
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: James ND
forenameInitials: ND
affiliation: University of Warwick, Coventry, UK. Electronic address: N.D.James@warwick.ac.uk.
entry
contributor: Spears MR
forenameInitials: MR
affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.
entry
contributor: Clarke NW
forenameInitials: NW
affiliation: Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.
entry
contributor: Dearnaley DP
forenameInitials: DP
affiliation: Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
entry
contributor: De Bono JS
forenameInitials: JS
affiliation: Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
entry
contributor: Gale J
forenameInitials: J
affiliation: Queen Alexandra Hospital, Portsmouth, UK.
entry
contributor: Hetherington J
forenameInitials: J
affiliation: Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
entry
contributor: Hoskin PJ
forenameInitials: PJ
affiliation: Mount Vernon Hospital, Northwood, Middlesex, UK.
entry
contributor: Jones RJ
forenameInitials: RJ
affiliation: University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
entry
contributor: Laing R
forenameInitials: R
affiliation: Royal Surrey County Hospital, Guildford, UK.
entry
contributor: Lester JF
forenameInitials: JF
affiliation: Velindre Hospital, Cardiff, UK.
entry
contributor: McLaren D
forenameInitials: D
affiliation: Western General Hospital, Edinburgh, UK.
entry
contributor: Parker CC
forenameInitials: CC
affiliation: Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
entry
contributor: Parmar MKB
forenameInitials: MKB
affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.
entry
contributor: Ritchie AWS
forenameInitials: AWS
affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.
entry
contributor: Russell JM
forenameInitials: JM
affiliation: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
entry
contributor: Strebel RT
forenameInitials: RT
affiliation: Kantonsspital Graübunden, Chur, Switzerland.
entry
contributor: Thalmann GN
forenameInitials: GN
affiliation: Department of Urology, University Hospital, Bern, Switzerland.
entry
contributor: Mason MD
forenameInitials: MD
affiliation: Velindre Hospital, Cardiff, UK.
entry
contributor: Sydes MR
forenameInitials: MR
affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK.

Generated Narrative: ArtifactAssessment #keywords0

artifact: Citation 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
content
classifier: Control arm cohort
content
classifier: Hormone-naïve
content
classifier: Metastatic
content
classifier: Natural history
content
classifier: Prognostic factors
content
classifier: Prospective data
content
classifier: Prostate cancer
content
classifier: Survival
content
classifier: Time to progression

Generated Narrative: Practitioner #contributor0

name: Nicholas David James

Generated Narrative: Practitioner #contributor1

name: Melissa R Spears

Generated Narrative: Practitioner #contributor2

name: Noel W Clarke

Generated Narrative: Practitioner #contributor3

name: David P Dearnaley

Generated Narrative: Practitioner #contributor4

name: Johann S De Bono

Generated Narrative: Practitioner #contributor5

name: Joanna Gale

Generated Narrative: Practitioner #contributor6

name: John Hetherington

Generated Narrative: Practitioner #contributor7

name: Peter J Hoskin

Generated Narrative: Practitioner #contributor8

name: Robert J Jones

Generated Narrative: Practitioner #contributor9

name: Robert Laing

Generated Narrative: Practitioner #contributor10

name: Jason F Lester

Generated Narrative: Practitioner #contributor11

name: Duncan McLaren

Generated Narrative: Practitioner #contributor12

name: Christopher C Parker

Generated Narrative: Practitioner #contributor13

name: Mahesh K B Parmar

Generated Narrative: Practitioner #contributor14

name: Alastair W S Ritchie

Generated Narrative: Practitioner #contributor15

name: J Martin Russell

Generated Narrative: Practitioner #contributor16

name: Räto T Strebel

Generated Narrative: Practitioner #contributor17

name: George N Thalmann

Generated Narrative: Practitioner #contributor18

name: Malcolm D Mason

Generated Narrative: Practitioner #contributor19

name: Matthew R Sydes

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
content
type: components (if present) include qualifier codings
classifier: Adult
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Age Factors
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Aged, 80 and over
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Cohort Studies
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Disease-Free Survival
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Docetaxel
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Early Detection of Cancer
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: mortality
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Follow-Up Studies
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Kaplan-Meier Estimate
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Neoplasm Grading
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Neoplasm Metastasis
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: diagnosis
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapy
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Physical Fitness
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Prognosis
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Proportional Hazards Models
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Prostate-Specific Antigen
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: diagnosis
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: mortality
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Risk Factors
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Taxoids
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Treatment Outcome
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic